Objective:

To investigate the influence of antiobesity medications (AOMs) on hypothalamic adult neurogenesis (hAN) and their potential neuroprotective effects in obesity management, with implications for broader treatment strategies.

Key Findings:

• AOMs preserve hypothalamic neural stem cells and reduce their activation during high-fat diet exposure.
• AOMs do not alter the proportion of anorexigenic POMC+ neurons in treated human and mouse models, indicating a stable ratio.
• AOMs may promote neuronal survival in the hypothalamus, potentially contributing to their anorexigenic effects.

Interpretation:

The findings suggest that AOMs influence hAN and neuronal survival in the hypothalamus, which may play a role in their effectiveness for obesity treatment, although they do not change the ratio of anorexigenic to orexigenic neurons, highlighting the need for further exploration of these mechanisms.

Limitations:

• The study did not demonstrate that hAN is necessary for the anorexigenic effects of AOMs, which limits the conclusions that can be drawn.
• Experiments were conducted under physiological conditions rather than obesity conditions, which may not fully represent the clinical scenario.
• Focus was on neuronal maturation rather than differentiation, which could affect the interpretation of neurogenic effects.

Conclusion:

Establishing a neurogenic hypothesis for obesity treatment could enhance understanding of AOMs' mechanisms, but further research is needed to clarify the role of hAN in their efficacy and to validate these findings.